PURPOSE: Circulating tumor cells (CTC) in peripheral blood of patients potentially represent a fraction of solid tumor cells available for more frequent pharmacodynamic assessment of drug action than is possible using tumor biopsy. However, currently available CTC assays are limited to cell membrane antigens. Here, we describe an assay that directly examines changes in levels of the nuclear DNA damage marker gammaH2AX in individual CTCs of patients treated with chemotherapeutic agents. EXPERIMENTAL DESIGN: An Alexa Fluor 488-conjugated monoclonal gammaH2AX antibody and epithelial cancer cell lines treated with topotecan and spiked into whole blood were used to measure DNA damage-dependent nuclear gammaH2AX signals in individual CTCs. Time-course changes in both CTC number and gammaH2AX levels in CTCs were also evaluated in blood samples from patients undergoing treatment. RESULTS: The percentage of gammaH2AX-positive CTCs increased in a concentration-dependent manner in cells treated with therapeutically relevant concentrations of topotecan ex vivo. In samples from five patients, percent gammaH2AX-positive cells increased post-treatment from a mean of 2% at baseline (range, 0-6%) to a mean of 38% (range, 22-64%) after a single day of drug administration; this increase was irrespective of increases or decreases in the total CTC count. CONCLUSIONS: These data show promise for monitoring dynamic changes in nuclear biomarkers in CTCs (in addition to CTC count) for rapidly assessing drug activity in clinical trials of molecularly targeted anticancer therapeutics as well as for translational research.
PURPOSE: Circulating tumor cells (CTC) in peripheral blood of patients potentially represent a fraction of solid tumor cells available for more frequent pharmacodynamic assessment of drug action than is possible using tumor biopsy. However, currently available CTC assays are limited to cell membrane antigens. Here, we describe an assay that directly examines changes in levels of the nuclear DNA damage marker gammaH2AX in individual CTCs of patients treated with chemotherapeutic agents. EXPERIMENTAL DESIGN: An Alexa Fluor 488-conjugated monoclonal gammaH2AX antibody and epithelial cancer cell lines treated with topotecan and spiked into whole blood were used to measure DNA damage-dependent nuclear gammaH2AX signals in individual CTCs. Time-course changes in both CTC number and gammaH2AX levels in CTCs were also evaluated in blood samples from patients undergoing treatment. RESULTS: The percentage of gammaH2AX-positive CTCs increased in a concentration-dependent manner in cells treated with therapeutically relevant concentrations of topotecan ex vivo. In samples from five patients, percent gammaH2AX-positive cells increased post-treatment from a mean of 2% at baseline (range, 0-6%) to a mean of 38% (range, 22-64%) after a single day of drug administration; this increase was irrespective of increases or decreases in the total CTC count. CONCLUSIONS: These data show promise for monitoring dynamic changes in nuclear biomarkers in CTCs (in addition to CTC count) for rapidly assessing drug activity in clinical trials of molecularly targeted anticancer therapeutics as well as for translational research.
Authors: A Dowlati; J Haaga; S C Remick; T P Spiro; S L Gerson; L Liu; S J Berger; N A Berger; J K Willson Journal: Clin Cancer Res Date: 2001-10 Impact factor: 12.531
Authors: W Jeffrey Allard; Jeri Matera; M Craig Miller; Madeline Repollet; Mark C Connelly; Chandra Rao; Arjan G J Tibbe; Jonathan W Uhr; Leon W M M Terstappen Journal: Clin Cancer Res Date: 2004-10-15 Impact factor: 12.531
Authors: P L Olive; R E Durand; S M Jackson; J C Le Riche; C Luo; R Ma; D B McLaren; C Aquino-Parsons; T A Thomson; T Trotter Journal: Acta Oncol Date: 1999 Impact factor: 4.089
Authors: Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes Journal: N Engl J Med Date: 2004-08-19 Impact factor: 91.245
Authors: Songdong Meng; Debasish Tripathy; Sanjay Shete; Raheela Ashfaq; Barbara Haley; Steve Perkins; Peter Beitsch; Amanullah Khan; David Euhus; Cynthia Osborne; Eugene Frenkel; Susan Hoover; Marilyn Leitch; Edward Clifford; Ellen Vitetta; Larry Morrison; Dorothee Herlyn; Leon W M M Terstappen; Timothy Fleming; Tanja Fehm; Thomas Tucker; Nancy Lane; Jianqiang Wang; Jonathan Uhr Journal: Proc Natl Acad Sci U S A Date: 2004-06-11 Impact factor: 11.205
Authors: Xuan Huang; Masaki Okafuji; Frank Traganos; Ed Luther; Elena Holden; Zbigniew Darzynkiewicz Journal: Cytometry A Date: 2004-04 Impact factor: 4.355
Authors: E Bölke; K Orth; P A Gerber; G Lammering; R Mota; M Peiper; C Matuschek; W Budach; E Rusnak; S Shaikh; B Dogan; H B Prisack; H Bojar Journal: Eur J Med Res Date: 2009-08-12 Impact factor: 2.175
Authors: Robert J Kinders; Melinda Hollingshead; Scott Lawrence; Jiuping Ji; Brian Tabb; William M Bonner; Yves Pommier; Larry Rubinstein; Yvonne A Evrard; Ralph E Parchment; Joseph Tomaszewski; James H Doroshow Journal: Clin Cancer Res Date: 2010-10-05 Impact factor: 12.531
Authors: Shivaani Kummar; Jiuping Ji; Robert Morgan; Heinz-Josef Lenz; Shannon L Puhalla; Chandra P Belani; David R Gandara; Deborah Allen; Brian Kiesel; Jan H Beumer; Edward M Newman; Larry Rubinstein; Alice Chen; Yiping Zhang; Lihua Wang; Robert J Kinders; Ralph E Parchment; Joseph E Tomaszewski; James H Doroshow Journal: Clin Cancer Res Date: 2012-02-03 Impact factor: 12.531
Authors: George Somlo; Sean K Lau; Paul Frankel; H Ben Hsieh; Xiaohe Liu; Lixin Yang; Robert Krivacic; Richard H Bruce Journal: Breast Cancer Res Treat Date: 2011-04-16 Impact factor: 4.872
Authors: Shivaani Kummar; Alice Chen; Martin Gutierrez; Thomas D Pfister; Lihua Wang; Christophe Redon; William M Bonner; William Yutzy; Yiping Zhang; Robert J Kinders; Jiuping Ji; Deborah Allen; Joseph M Covey; Julie L Eiseman; Julianne L Holleran; Jan H Beumer; Larry Rubinstein; Jerry Collins; Joseph Tomaszewski; Ralph Parchment; Yves Pommier; James H Doroshow Journal: Cancer Chemother Pharmacol Date: 2016-05-11 Impact factor: 3.333
Authors: Susan L Holbeck; Richard Camalier; James A Crowell; Jeevan Prasaad Govindharajulu; Melinda Hollingshead; Lawrence W Anderson; Eric Polley; Larry Rubinstein; Apurva Srivastava; Deborah Wilsker; Jerry M Collins; James H Doroshow Journal: Cancer Res Date: 2017-04-26 Impact factor: 12.701
Authors: Elizabeth A Punnoose; Siminder K Atwal; Jill M Spoerke; Heidi Savage; Ajay Pandita; Ru-Fang Yeh; Andrea Pirzkall; Bernard M Fine; Lukas C Amler; Daniel S Chen; Mark R Lackner Journal: PLoS One Date: 2010-09-08 Impact factor: 3.240